Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f52c68e4149a6c462b850d4e7cc2b2f9 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
filingDate |
2017-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac69b43935220345fd09f7e6f576df47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4008e9017d4b1cae5df25d370d60b0aa |
publicationDate |
2018-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
DE-102017008472-A1 |
titleOfInvention |
Combination containing PDE5 inhibitors and mineralocorticoid receptor antagonists |
abstract |
The present invention relates to the combination of inhibitors of phosphodiesterase type 5 (PDE5 inhibitors) with mineralocorticoid receptor antagonists (MR antagonists) and the use of the combination for the treatment and / or prophylaxis of cardiovascular diseases, kidney and cardio-renal diseases, pulmonary and cardio-pulmonary diseases, as well as for the treatment and / or prophylaxis of fibrotic diseases. |
priorityDate |
2017-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |